Terazosin
=========
Somebody in a different forum posted that the best medicine they are taking for PD is Terazosin off label. He said his movement specialist said he was better now than he was 7 years ago.
I see Terazosin has been posted about before here, but did not get much attention.
There are 2 trials going on:
--------------------
Terazosin for Parkinson's Disease (TZ-PD) Trial
Drug: Terazosin 5 MG
clinicaltrials.gov/ct2/show...
--------------------
Terazosin Effect on Cardiac Changes in Early Parkinson's Disease Trial Recruiting
clinicaltrials.gov/ct2/show...
--------------------
And a sprinkling of stories:
--------------------
Could a prostate drug slow or stop Parkinson’s?
medium.com/parkinsons-uk/co...
Further evidence emerges to suggest that terazosin — a drug currently used to treat enlarged prostate — may have the potential to slow or stop Parkinson’s.
--------------------
Recent developments in the treatment of Parkinson's Disease 2020
ncbi.nlm.nih.gov/pmc/articl...
Terazosin, an α 1-adrenergic antagonist used in benign prostatic hypertrophy, has recently emerged as a putative treatment for PD. Terazosin has been found to activate phosphoglycerate kinase-1 and the chaperone protein HSP90, which is involved in multiple intracellular stress responses 46. It has been shown to have neuroprotective effects in neurotoxin models of nigrostriatal degeneration in invertebrates and rodents, including after delayed administration 35. Additionally, terazosin reduced α-synuclein levels in transgenic mice and in neurons derived from patients with LRRK2 mutation-associated PD 35. Furthermore, a retrospective epidemiological study found that people taking terazosin have a reduced relative risk of PD 35. These promising findings have led to terazosin rapidly progressing to a randomised placebo-controlled trial, which will involve 20 patients with Hoehn and Yahr stage 3 PD (NCT03905811). However, terazosin reduces blood pressure and can cause orthostatic hypotension, which is a problem in many patients with advancing PD and may limit its applicability in this disease.
--------------------
Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases 2019
Impaired energy metabolism and reduced ATP levels are common features of PD. Previous studies revealed that terazosin (TZ) enhances the activity of phosphoglycerate kinase 1 (PGK1), thereby stimulating glycolysis and increasing cellular ATP levels. Therefore, we asked whether enhancement of PGK1 activity would change the course of PD. In toxin-induced and genetic PD models in mice, rats, flies, and induced pluripotent stem cells, TZ increased brain ATP levels and slowed or prevented neuron loss. The drug increased dopamine levels and partially restored motor function. Because TZ is prescribed clinically, we also interrogated 2 distinct human databases. We found slower disease progression, decreased PD-related complications, and a reduced frequency of PD diagnoses in individuals taking TZ and related drugs.
--------------------
Blood Pressure and Prostate Treatment May Prevent or Slow Parkinson’s, Early Study Suggests - 2019
parkinsonsnewstoday.com/201...
Hytrin was found to increase brain ATP levels and slow or prevent nerve cell loss in several models of Parkinson’s (MPTP, rotenone and 6-OHDA-induced or genetic models): mice, rats, flies, and induced pluripotent stem cells. MPTP, rotenone and 6-OHDA are all neurotoxins that induce death of dopamine-producing neurons and mimic Parkinson’s symptoms.
Treatment with this medication increased brain dopamine levels — the chemical messenger that is present in low levels in the brains of Parkinson’s patients — and partially restored motor function in both mice and flies.
Importantly, boosting PGK1 activity was beneficial even when treatment was initiated after the onset of neurodegeneration, suggesting the modulation of this protein’s function could help to slow Parkinson’s progression.
Sounds very interesting to me.
I know one person on this forum's PwP's ankles swelled up, so it is not perfect. Interesting though.